ArticleFrontiers in psychiatry2026
Efficacy and neural mechanisms of transcutaneous auricular vagus nerve stimulation for chronic insomnia: a study protocol for a randomized controlled trial.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traditional auricular therapy for chronic insomnia ( Methods: This protocol will recruit 60 patients with chronic insomnia disorder (CID) and 30 age- and sex-matched healthy controls (HCs). Patients with CID will be randomized 1:1 to receive 4 weeks of active or sham-taVNS. Resting-state functional magnetic resonance imaging (rs-fMRI) will be performed at baseline in all participants and repeated at Week 4 in patients with CID, within 24 hours after the final intervention session. Fractional amplitude of low-frequency fluctuation (fALFF) will serve as a prespecified exploratory neuroimaging measure, with amplitude of low-frequency fluctuation (ALFF) included as a complementary exploratory measure. The neuroimaging analyses will examine baseline differences between patients with CID and HCs and between-group differences in baseline-to-Week-4 changes between the active and sham-taVNS groups to characterize brain functional alterations associated with CID and changes associated with active taVNS relative to sham-taVNS. The primary clinical outcome will be the change in Pittsburgh Sleep Quality Index (PSQI) score from baseline to Week 4. Secondary and follow-up assessments will evaluate insomnia severity, daytime sleepiness, emotional status, cognitive function, pre-sleep arousal, and quality of life. Exploratory correlations between changes in neuroimaging measures and clinical outcomes will also be examined. Discussion: This study will integrate clinical assessments with rs-fMRI to evaluate the clinical effects of taVNS in patients with CID and explore associated changes in spontaneous brain activity. The integration of clinical outcomes and exploratory neuroimaging measures may provide complementary evidence on treatment effects and associated brain functional changes, thereby informing future investigation of the potential neural mechanisms of taVNS in CID. Clinical Trial Registration: https://www.chictr.org.cn/hvshowprojectEN.html?id=277442&v=1.0, identifier ChiCTR2500103157.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.